Matsushita Tadashi
Department of Transfusion Medicine, Nagoya University Hospital.
Rinsho Ketsueki. 2015 Oct;56(10):2100-9. doi: 10.11406/rinketsu.56.2100.
Hemophilia is a rare bleeding disorder, for which treatments are still being developing and several new agents are providing better quality of life for patents. National evidence- and/or practice-based guidelines have been published by JSTH. Recommendations offered for the hemostatic management of hemophilia have assisted healthcare providers in initiating general hemophilia care. This article first reviews the two national guidelines for patients with/without inhibitor treatments. Then, future perspectives on progress in current treatment as well as the newer agents are summarized. Treatment options anticipated to be available in the near future are proposed for all caregivers in Japan.
血友病是一种罕见的出血性疾病,针对该疾病的治疗仍在不断发展,一些新型药物正在为患者提供更高的生活质量。日本血栓与止血学会(JSTH)已发布了基于国家证据和/或实践的指南。针对血友病止血管理提出的建议,有助于医疗服务提供者开展一般血友病护理。本文首先回顾了针对有/无抑制剂治疗患者的两项国家指南。然后,总结了当前治疗进展以及新型药物的未来前景。为日本所有护理人员提出了预计在不久的将来可用的治疗选择。